Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 7NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Ovarian Neoplasms 43Lung Neoplasms 41Fallopian Tube Neoplasms 29Carcinoma, Ovarian Epithelial 28Breast Neoplasms 22Neuroblastoma 18Adenocarcinoma of Lung 17Central Nervous System Neoplasms 16Brenner Tumor 12Endometrial Neoplasms 9Adenocarcinoma, Bronchiolo-Alveolar 9Testicular Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Astrocytoma 8Unspecified Adult Solid Tumor, Protocol Specific 7Triple Negative Breast Neoplasms 7Oligodendroglioma 7Lymphoma, Large B-Cell, Diffuse 7Brain Neoplasms 7Head and Neck Neoplasms 6Teratoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Medulloblastoma 5Leukemia, Myeloid, Acute 5Gliosarcoma 5Glioblastoma 5Thrombocythemia, Essential 4Testicular Germ Cell Tumor 4

Interventions

Magnetic Resonance Spectroscopy 9X-Rays 6Specimen Handling 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Temozolomide 4Carmustine 4Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2Surgical Procedures, Operative 2Radiotherapy 2Lapatinib 2LY3023414 2Filgrastim 2Cyclophosphamide 2Congresses as Topic 2Cisplatin 2Bevacizumab 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ependymoma × Carboplatin × Clear all
NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
35 enrolled 17 charts
CNS

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡